Myrac Side Effects
Generic name: minocycline
Note: This document contains side effect information about minocycline. Some of the dosage forms listed on this page may not apply to the brand name Myrac.
Some side effects of Myrac may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to minocycline: oral capsule, oral capsule extended release, oral suspension, oral tablet, oral tablet extended release
Along with its needed effects, minocycline (the active ingredient contained in Myrac) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking minocycline:Incidence not known
- Black, tarry stools
- blistering, peeling, or loosening of the skin
- blood in the urine or stools
- blurred or double vision
- bulging soft spot on the head of an infant
- chest pain, possibly moving to the left arm, neck, or shoulder
- dizziness or lightheadedness
- eye pain
- fast heartbeat
- general feeling of discomfort or illness
- general tiredness and weakness
- hives, itching, or skin rash
- joint or muscle pain
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
- loss of appetite
- nausea or vomiting
- red skin lesions, often with a purple center
- severe headache
- severe stomach pain
- shortness of breath or troubled breathing
- sores, ulcers, or white spots on the lips or in the mouth
- unusual bleeding or bruising
- upper right abdominal or stomach pain
- yellow eyes and skin
Some side effects of minocycline may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:Less common
- Continuing ringing or buzzing or other unexplained noise in the ears
- difficulty with moving
- hearing loss
- hives or welts
- muscle stiffness
- redness of the skin
- sleepiness or unusual drowsiness
- discoloration of the tooth
- increased sensitivity of the skin to sunlight
- severe sunburn
For Healthcare Professionals
Applies to minocycline: intravenous powder for injection, oral capsule, oral suspension, oral tablet, oral tablet extended release, oral and topical kit
Gastrointestinal side effects have included abdominal cramping, anorexia, diarrhea, dyspepsia, dysphagia, enamel hypoplasia, enterocolitis, esophagitis, esophageal ulcerations, glossitis, nausea, oral cavity and tooth discoloration, inflammatory lesions (with monilial overgrowth) in the oral and anogenital regions, pancreatitis, pseudomembranous colitis, stomatitis, vomiting, and dry mouth.
Pancreatitis has rarely been reported in association with minocycline use. Two case reports of cystic fibrosis patients who experienced pancreatitis while being treated with minocycline for acute bacterial exacerbations of respiratory disease have been published in the medical literature. The authors suggested that cystic fibrosis patients, as a result of the disease process, may be more susceptible to drug-induced pancreatitis. Additionally, in at least one case, multiple medications were being given concomitantly; therefore, a temporal relationship between minocycline and pancreatitis could not be proven conclusively.
Esophagitis and esophageal ulcerations have been reported in patients taking the capsule or tablet formulations of tetracycline-class antibiotics. Most of these patients took the drug immediately before going to bed.
Nervous system side effects have included convulsions, headache, hypesthesia, paresthesia, sedation, vestibular reactions including dizziness and vertigo. Decreased hearing, tinnitus, benign intracranial hypertension (pseudotumor cerebri) in adults, and bulging fontanels in infants have been reported.
In one reported case, a patient developed rapidly progressing liver failure after four weeks of minocycline (the active ingredient contained in Myrac) therapy for acne. The patient had discontinued the medication two weeks prior to onset of malaise. Liver transplantation was considered, although the patient slowly recovered without significant intervention.
Other reports of immunologically-mediated progressive liver dysfunction have rarely occurred. In one case, a patient received a liver transplant following fulminant hepatic failure which was thought to be related to a 3 year history of daily minocycline therapy to treat acne. The dose of minocycline ranged from 50 mg to 200 mg per day. A second patient had been receiving minocycline therapy to treat acne for 1 year just prior to seeking medical attention for a "flu-like" syndrome. Upon hospitalization, it was determined that the patient was experiencing an autoimmune-mediated hepatitis, most probably related to minocycline. Resolution of symptoms occurred in both of these cases after minocycline therapy was discontinued and each patient had received appropriate supportive medical care.
Hepatic side effects have included hyperbilirubinemia, hepatic cholestasis, increased liver enzymes, fatal hepatic failure, jaundice, hepatitis (including autoimmune hepatitis), and liver failure.
Hypersensitivity side effects have included anaphylactoid purpura, anaphylaxis/anaphylactoid reaction (including shock and fatalities), angioneurotic edema, autoimmune vasculitis, drug fever, eosinophilic pneumonitis, erythema multiforme, fixed drug eruptions, hepatitis, lupus-like syndrome, myocarditis, pericarditis, polyarthralgia, pulmonary infiltrates with eosinophilia, rhabdomyolysis, serum sickness, serum sickness-like reactions, Stevens-Johnson syndrome, urticaria, and severe central nervous system-pulmonary hypersensitivity syndrome. Drug rash with eosinophilia and systemic symptoms (DRESS) including fatal cases have been reported. DRESS syndrome with persistent myocarditis has been reported in at least 3 cases. Hypersensitivity syndrome (consisting of cutaneous reaction such as rash or exfoliative dermatitis, eosinophilia, and one or more of the following: hepatitis, pneumonitis, nephritis, myocarditis, and pericarditis) has been reported. Fever and lymphadenopathy may be present with hypersensitivity syndrome. Death has been reported in some cases involving hypersensitivity syndrome.
Pulmonary infiltrates, night sweats, fever and eosinophilia have developed in several patients receiving minocycline. These effects were also thought to be due to hypersensitivity to minocycline.
Case reports have described a severe central nervous system-pulmonary hypersensitivity syndrome requiring high-dose corticosteroid therapy. Signs and symptoms have included dry cough, fever, ataxia, muscle weakness, numbness, visual abnormalities, abnormal brain MRI, seizures, pulmonary infiltrates, elevated serum IgE and erythrocyte sedimentation rate, and eosinophilia.
Eosinophilic pneumonia with relapsing acute respiratory failure requiring mechanical ventilation and corticosteroids has been reported in a 54-year-old woman. Initial symptoms included dry cough, low-grade fever, fatigue, and dyspnea. Eosinophilia, elevated leukocytes, and C-reactive protein were noted. Fourteen days after being discharged and resuming minocycline, the patient developed rapidly progressive respiratory failure again requiring mechanical ventilation.
Late-onset drug fever (associated with fever, sore throat, abdominal pain, weakness, loose bloody stools, fatigue, 40-pound weight loss, ESR 99 mm/hr, CRP 5.0 mg/dL, and mild increases in liver enzymes) has been reported in a 15-year-old boy after 24 months of minocycline therapy for acne. One other case of late-onset drug fever occurred after 1 year of treatment. Other reported cases of drug fever generally occurred after 2 to 4 weeks of minocycline exposure.
Lupus-like reactions induced by minocycline (the active ingredient contained in Myrac) have commonly presented with arthralgia or arthritis, myalgia or malaise, and positive ANA titer. Patients with highly positive anti-dsDNA antibodies have rarely been reported. All patients have recovered following discontinuation of the drug. However, several have required short courses of corticosteroids.
Rare case reports of additional immunologic side effects have included necrotizing vasculitis and systemic reactions characterized by lymphadenopathy, eosinophilia, increased liver function enzyme levels, and dermatologic involvement. In each case, minocycline was discontinued and in some cases, corticosteroid therapy was necessary to assist in the resolution of symptoms.
Immunologic side effects have included positive antineutrophil cytoplasmic antibody (ANCA) titers, exacerbation of systemic lupus, polyarteritis nodosa, ANCA-positive crescentic glomerulonephritis, ANCA-positive vasculitis, and autoimmune hepatitis. Rare cases of necrotizing vasculitis and systemic reactions have been reported. Lupus-like syndrome (consisting of positive antinuclear antibody; arthralgia, arthritis, joint stiffness, or joint swelling; and one or more of the following: fever, myalgia, hepatitis, rash, and vasculitis) has been reported. Serum sickness-like syndrome (consisting of fever; urticaria or rash; and arthralgia, arthritis, joint stiffness, or joint swelling) has been reported. Eosinophilia may be present with serum sickness-like syndrome. Death has been reported in some cases involving these syndromes.
Dermatologic side effects have included pruritus, alopecia, erythema multiforme, erythema nodosum, exfoliative dermatitis, fixed drug eruptions, maculopapular and erythematous rashes, photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis, lesions on the glans penis, and vasculitis. Brownish or bluish-black pigmentation of the skin, bones, mucous membranes, teeth, tongue, nail beds, and structures of inner organs have also been reported. Minocycline (the active ingredient contained in Myrac) has rarely been associated with Sweet's syndrome (acute febrile neutrophilic dermatosis).
Biopsies of pigmented tissue have shown granules within the cells which stained positive for iron. This pigmentation may fade over time following drug discontinuation.
There have also been case reports of mucosal pigmentation associated with minocycline use.
Musculoskeletal side effects have included arthralgia, arthritis, bone discoloration, joint discoloration, joint stiffness, joint swelling, myalgia, myopathy, and hypersensitivity-associated rhabdomyolysis.
Severe acute myopathy associated with oral minocycline 100 mg/day occurred in a 17-year-old male after strenuous exercise. His laboratory values were: erythrocyte sedimentation rate, 33 mm/hr; C-reactive protein, 0.84 mg/dL; creatine kinase, 87,297 units/L; AST, 1307 units/L; ALT, 311 units/L; lactate dehydrogenase, 4935 units/L; aldolase 12.6 units/L; alkaline phosphatase, 145 units/L; GGT, 66 units/L. Muscle enzyme levels normalized and his symptoms resolved one month after minocycline was discontinued.
Intravenous minocycline plus quinupristin-dalfopristin were associated with myalgia and arthralgia in 36% of neutropenic cancer patients (n=56).
Renal side effects have included increased BUN, interstitial nephritis, and acute renal failure. High serum levels of tetracyclines have been associated with azotemia, hyperphosphatemia, and acidosis in renally impaired patients.
Hematologic side effects have included antineutrophil cytoplasmic antibody (ANCA)-positive vasculitis, and eosinophilia. Tetracyclines have been associated with hemolytic anemia, thrombocytopenia, neutropenia, agranulocytosis, leukopenia, and pancytopenia.
Other side effects associated with tetracyclines have included fatigue, malaise, somnolence, fever, and discoloration of secretions.
Respiratory side effects have included hypersensitivity pneumonitis, pulmonary lupus, eosinophilic pneumonia, pleural effusions, and relapsing acute respiratory failure. Tetracyclines have been associated with cough, dyspnea, bronchospasm, pneumonitis, and exacerbation of asthma.
Oncologic side effects have included papillary thyroid cancer. Thyroid cancer has also been reported during postmarketing experience.
Endocrine system side effects have included a condition characterized by dark pigmentation (brown-black microscopic discoloration) of the thyroid gland. However, there was no clinical or laboratory evidence of thyroid dysfunction. The clinical implications of this pigmentation are unknown. Abnormal thyroid function has been reported.
Genitourinary side effects have included balanitis (due to lesions on the glans penis) and vulvovaginitis. Minocycline (the active ingredient contained in Myrac) may have detrimental effects on spermatogenesis according to preliminary studies.
Local side effects have included erythema and pain at the injection site.
Psychiatric side effects have included mood alteration.
Ocular side effects have included case reports of gray scleral pigmentation and macular pigmentation in elderly patients after chronic minocycline (the active ingredient contained in Myrac) use (5 to 12 years).
More Myrac resources
- Myrac Advanced Consumer (Micromedex) - Includes Dosage Information
- Myrac MedFacts Consumer Leaflet (Wolters Kluwer)
- Minocycline Professional Patient Advice (Wolters Kluwer)
- Minocycline Prescribing Information (FDA)
- Dynacin Prescribing Information (FDA)
- Minocin MedFacts Consumer Leaflet (Wolters Kluwer)
- Minocin Prescribing Information (FDA)
- Minocycline Hydrochloride Monograph (AHFS DI)
- Solodyn Prescribing Information (FDA)
- Solodyn extended-release tablets MedFacts Consumer Leaflet (Wolters Kluwer)
- Solodyn Consumer Overview
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.